Other Stories

Drug safety ministry revokes license of arthritis drug Invossa for mislabeling cell ingredient Updated: 2019-07-03 16:30:26 KST

South Korea's drug safety ministry says it is revoking the license of gene therapy drug Invossa, effective next Tuesday, after its maker was found to have mislabeled the active ingredient.
A treatment for knee arthritis, the drug firm claimed Invossa is made from cartilage cells, but it's been found that the cells were derived from kidneys, and could develop into cancer.
The ministry said the drug firm Kolon Life Science failed to explain why the cell ingredient is different from what they labeled at a hearing in mid-June.
The company said it will file a complaint to protest the ministry's decision.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.